URGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
URGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, UroGen Pharma's Trailing 12-Month Free Cash Flow is $-96.77 Mil, and Market Cap is $509.34 Mil. Therefore, UroGen Pharma's FCF Yield % for today is -18.98%.
The historical rank and industry rank for UroGen Pharma's FCF Yield % or its related term are showing as below:
During the past 10 years, the highest FCF Yield % of UroGen Pharma was 2.67%. The lowest was -66.71%. And the median was -17.65%.
UroGen Pharma's FCF Margin % for the quarter that ended in Dec. 2024 was -55.44%.
The historical data trend for UroGen Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
-26.81 | -40.09 | -42.80 | -15.71 | -21.58 |
UroGen Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-10.71 | -23.42 | -13.75 | -20.65 | -12.11 |
For the Biotechnology subindustry, UroGen Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, UroGen Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
UroGen Pharma's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -97.061 | / | 449.7708 | |
= | -21.58% |
UroGen Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -13.619 | * | 4 | / | 449.7708 | |
= | -12.11% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of UroGen Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark Schoenberg | officer: Chief Medical Officer | C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007 |
Jason Drew Smith | officer: General Counsel | C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540 |
Robinson James A. Jr. | director | 852 WINTER STREET, WALTHAM MA 02451 |
Daniel George Wildman | director | 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414 |
Leana Wen | director | C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
Dong Kim | officer: Chief Financial Officer | C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540 |
Elizabeth A. Barrett | officer: Chief Executive Officer | C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Molly Henderson | officer: Chief Financial Officer | 305 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Peter P. Pfreundschuh | officer: CFO | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Stephen Mullennix | officer: COO | C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Ran Nussbaum | director | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Stuart Holden | director | C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007 |
Cynthia M Butitta | director | 3165 PORTER DRIVE, PALO ALTO CA 94304 |
Ron Bentsur | director, officer: Chief Executive Officer | 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022 |
Fred E Cohen | director | 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
From GuruFocus
By GuruFocus News • 11-07-2024
By GuruFocus News • 03-12-2025
By Business Wire • 11-26-2024
By GuruFocus News • 10-09-2024
By Business Wire • 02-24-2025
By Business Wire • 11-06-2024
By GuruFocus News • 10-09-2024
By Business Wire • 10-15-2024
By GuruFocus News • 11-06-2024
By GuruFocus News • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.